form_type
stringclasses 2
values | accession_number
stringlengths 20
20
| filing_date
stringlengths 14
14
| quarter_ending
stringclasses 451
values | company_name
stringlengths 2
58
| text
stringlengths 101
9.36k
| entities
listlengths 1
50
|
|---|---|---|---|---|---|---|
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | Depreciation and amortization expense for the three months ended January 28, 2023 and January 31, 2022 was $2.3 million and $1.3 million, respectively. Depreciation and amortization expense for the nine months ended January 28, 2023 and January 31, 2022 was $6.5 million and $3.3 million, respectively. Computer equipment and software primarily includes electronic design automation software relating to the Company’s R&D design of future products and intellectual properties. Construction in progress and production equipment primarily includes mask set costs capitalized relating to the Company’s new products already introduced or to be introduced. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 111,
"End date for period": "2023-01-28",
"Label": "us-gaap:DepreciationDepletionAndAmortization",
"Start character": 108,
"Start date for period": "2022-10-30",
"Value": 2300000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 128,
"End date for period": "2022-01-31",
"Label": "us-gaap:DepreciationDepletionAndAmortization",
"Start character": 125,
"Start date for period": "2021-11-01",
"Value": 1300000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 262,
"End date for period": "2023-01-28",
"Label": "us-gaap:DepreciationDepletionAndAmortization",
"Start character": 259,
"Start date for period": "2022-05-01",
"Value": 6500000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 279,
"End date for period": "2022-01-31",
"Label": "us-gaap:DepreciationDepletionAndAmortization",
"Start character": 276,
"Start date for period": "2021-05-01",
"Value": 3300000
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | During the three months ended January 28, 2023, the Company recorded $2.4 million impairment charges primarily related to an impairment on property and equipment. The impairment charges were presented under | [
{
"Currency / Unit": "iso4217:USD",
"End character": 73,
"End date for period": "2023-01-28",
"Label": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
"Start character": 70,
"Start date for period": "2022-10-30",
"Value": 2400000
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | As of January 28, 2023, the total value of non-cancelable purchase orders payable within the next one year that were committed with the Company’s third party subcontractors was approximately $2.2 million. Such purchase commitments are included in the preceding table. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 195,
"End date for period": "2023-01-28",
"Label": "crdo:PurchaseObligationToBePaidWithinTheNextYear",
"Start character": 192,
"Start date for period": "2023-01-28",
"Value": 2200000
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | The Company entered into a manufacturing supply capacity reservation agreement with an assembly subcontractor during the current fiscal year due to the current global supply shortage environment. Under this arrangement, the Company agreed to pay refundable deposits to the supplier in exchange for reserved manufacturing production capacity over the term of the agreement, which approximates five years. In addition, the Company committed to certain purchase levels that were in line with the capacity reserved. If the Company does not meet the purchase level commitment, the agreement requires the Company to pay a fee equal to the difference between the actual purchase and the purchase commitment, up to the value of refundable deposits made. The Company currently estimates that it has made purchase level commitments of at least $35.5 million for the fiscal 2024 through fiscal 2028 | [
{
"Currency / Unit": "iso4217:USD",
"End character": 839,
"End date for period": "2023-01-28",
"Label": "crdo:RecordedUnconditionalPurchaseObligationToBePaidYearOneThroughFive",
"Start character": 835,
"Start date for period": "2023-01-28",
"Value": 35500000
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | under the capacity reservation agreement. Such purchase commitments are included in the preceding table. In addition, refundable deposits of $2.0 million were paid as of January 28, 2023, and refundable deposits payable under this arrangement are $3.4 million during the remainder of fiscal 2023 and $3.4 million in fiscal 2024. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 145,
"End date for period": "2023-01-28",
"Label": "us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases",
"Start character": 142,
"Start date for period": "2022-05-01",
"Value": 2000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 251,
"End date for period": "2023-01-28",
"Label": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
"Start character": 248,
"Start date for period": "2023-01-28",
"Value": 3400000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 304,
"End date for period": "2023-01-28",
"Label": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
"Start character": 301,
"Start date for period": "2023-01-28",
"Value": 3400000
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | Immediately prior to the completion of the IPO during the quarter ended January 31, 2022, all of the then outstanding 52,059,826 shares of the Company’s convertible Preferred Shares were automatically converted into an aggregate 52,059,826 shares of ordinary shares on a one-for-one basis, and such Preferred Shares were cancelled, retired and eliminated from the shares that the Company is authorized to issue and shall not be reissued by the Company. | [
{
"Currency / Unit": "xbrli:shares",
"End character": 128,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquitySharesOutstanding",
"Start character": 118,
"Start date for period": "2022-01-30",
"Value": 52059826
},
{
"Currency / Unit": "xbrli:shares",
"End character": 239,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquitySharesOutstanding",
"Start character": 229,
"Start date for period": "2022-01-30",
"Value": 52059826
},
{
"Currency / Unit": "xbrli:shares",
"End character": 274,
"End date for period": "2022-01-30",
"Label": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
"Start character": 271,
"Start date for period": "2022-01-30",
"Value": 1
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | be equal to the original issue price of such series, which means $1.00 per share for Series A, $2.10 per share for Series B, $4.29 per share for Series C, $4.99 per share for Series D and $5.81 per share for Series D+. The conversion price shall be subject to adjustment in order to adjust the number of ordinary shares into which the Preferred Shares are convertible. | [
{
"Currency / Unit": null,
"End character": 70,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
"Start character": 66,
"Start date for period": "2022-01-30",
"Value": 1
},
{
"Currency / Unit": null,
"End character": 100,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
"Start character": 96,
"Start date for period": "2022-01-30",
"Value": 2.1
},
{
"Currency / Unit": null,
"End character": 130,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
"Start character": 126,
"Start date for period": "2022-01-30",
"Value": 4.29
},
{
"Currency / Unit": null,
"End character": 160,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
"Start character": 156,
"Start date for period": "2022-01-30",
"Value": 4.99
},
{
"Currency / Unit": null,
"End character": 193,
"End date for period": "2022-01-30",
"Label": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
"Start character": 189,
"Start date for period": "2022-01-30",
"Value": 5.8100000000000005
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | Each share of each series of Preferred Shares automatically converted into the number of ordinary shares at the conversion rate at the time in effect upon the closing of a public offering of ordinary shares which results in at least $25.0 million of proceeds to the Company at a per share price not less than $9.99 or with the vote or written consent of the holders of a majority of the then outstanding Preferred Shares, voting as a separate class, to convert their Preferred Shares at the then effective Conversion Price. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 238,
"End date for period": "2022-01-31",
"Label": "crdo:TemporaryEquityConversionThresholdMinimumConsiderationReceivedOnSaleOfStock",
"Start character": 234,
"Start date for period": "2022-01-31",
"Value": 25000000
},
{
"Currency / Unit": null,
"End character": 314,
"End date for period": "2022-01-31",
"Label": "crdo:TemporaryEquityConversionThresholdMinimumPricePerShareOnSaleOfStock",
"Start character": 310,
"Start date for period": "2022-01-31",
"Value": 9.99
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | - The holders of Preferred Shares were entitled to receive noncumulative dividends when and if declared by the Company’s board of directors. The holders of Preferred Shares were entitled to receive dividends prior and in preference to any payment of any dividend on ordinary shares in an amount equal to 8% of the original issue price per share of such Preferred Share. After payment of such dividends, any additional dividends shall be distributed among all holders of ordinary shares and Preferred Shares in proportion to the number of ordinary shares that would be held by each such holder if all Preferred Shares were converted to ordinary shares at the then effective conversion rate. No dividends had been declared by the board of directors from inception through the date of conversion into ordinary shares. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 305,
"End date for period": "2022-01-31",
"Label": "crdo:TemporaryEquityDividendRatePercentage",
"Start character": 304,
"Start date for period": "2022-01-31",
"Value": 0.08
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | As of January 28, 2023, the weighted average remaining lease term for the Company's operating leases is 6.94 years and the weighted average discount rate used to determine the present value of the Company's operating leases is 5.81%. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 231,
"End date for period": "2023-01-28",
"Label": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
"Start character": 227,
"Start date for period": "2023-01-28",
"Value": 0.058100000000000006
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | The Company has issued ordinary shares to certain employees that are subject to vesting periods pursuant to the respective share purchase agreements (“Restricted Share Awards” or “RSAs”). In addition, the Company allows early exercise for unvested ordinary share options granted under its 2015 Stock Plan. In regard to the ordinary shares purchased, but not vested, the Company has the right to repurchase shares at the original issue price in the event of termination of services. As of January 28, 2023, 127,780 shares from share option early exercises remained subject to the Company’s repurchase rights. As of April 30, 2022, 442,787 such ordinary shares, consisting of 16,667 shares from RSAs and 426,120 from share option early exercises, remained subject to the Company’s repurchase rights. These shares are excluded from ordinary shares outstanding. | [
{
"Currency / Unit": "xbrli:shares",
"End character": 513,
"End date for period": "2023-01-28",
"Label": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
"Start character": 506,
"Start date for period": "2023-01-28",
"Value": 127780
},
{
"Currency / Unit": "xbrli:shares",
"End character": 638,
"End date for period": "2022-04-30",
"Label": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
"Start character": 631,
"Start date for period": "2022-04-30",
"Value": 442787
},
{
"Currency / Unit": "xbrli:shares",
"End character": 681,
"End date for period": "2022-04-30",
"Label": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
"Start character": 675,
"Start date for period": "2022-04-30",
"Value": 16667
},
{
"Currency / Unit": "xbrli:shares",
"End character": 710,
"End date for period": "2022-04-30",
"Label": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
"Start character": 703,
"Start date for period": "2022-04-30",
"Value": 426120
}
] |
10-Q | 0001628280-23-006114 | 20230302172805 | 20230128 | Credo Technology Group Holding Ltd | During the three and nine months ended January 28, 2023, 92,607 shares and 246,660 shares, respectively, were issued under the ESPP. | [
{
"Currency / Unit": "xbrli:shares",
"End character": 63,
"End date for period": "2023-01-28",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
"Start character": 57,
"Start date for period": "2022-10-30",
"Value": 92607
},
{
"Currency / Unit": "xbrli:shares",
"End character": 82,
"End date for period": "2023-01-28",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
"Start character": 75,
"Start date for period": "2022-05-01",
"Value": 246660
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | The
accompanying unaudited consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, Simplicity
Esports, LLC, PLAYlive, Simplicity Union Gap, LLC, Simplicity Kennewick, LLC, Simplicity Humble, LLC, Simplicity Frisco, LLC, Simplicity
Billings, LLC, Simplicity Brea, LLC, Simplicity Santa Rosa, LLC, Simplicity St. Louis, LLC, Simplicity St. Petersburg, LLC, Simplicity
Fullerton, LLC, Simplicity Salinas, LLC, Simplicity Tracy, LLC, Simplicity Vancouver, LLC, Simplicity Fort Bliss, LLC, and PLAYlive Nation
Holdings, LLC; its 59% owned subsidiary Simplicity One Brasil Ltda. (“Simplicity One”); its 79% owned subsidiaries Simplicity
Happy Valley, LLC and Simplicity Redmond, LLC; and its 51% owned subsidiary Simplicity El Paso. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 577,
"End date for period": "2022-11-30",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 575,
"Start date for period": "2022-11-30",
"Value": 0.59
},
{
"Currency / Unit": "xbrli:pure",
"End character": 650,
"End date for period": "2022-11-30",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 648,
"Start date for period": "2022-11-30",
"Value": 0.79
},
{
"Currency / Unit": "xbrli:pure",
"End character": 739,
"End date for period": "2022-11-30",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 737,
"Start date for period": "2022-11-30",
"Value": 0.51
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | During
the three months ended November 30, 2022, and 2021, the Company recorded depreciation expense of $1,543 and $83,916, respectively. During
the six months ended November 30, 2022, and 2021, the Company recorded depreciation expense of $19,591 and $165,653, respectively. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 110,
"End date for period": "2022-11-30",
"Label": "us-gaap:Depreciation",
"Start character": 105,
"Start date for period": "2022-09-01",
"Value": 1543
},
{
"Currency / Unit": "iso4217:USD",
"End character": 122,
"End date for period": "2021-11-30",
"Label": "us-gaap:Depreciation",
"Start character": 116,
"Start date for period": "2021-09-01",
"Value": 83916
},
{
"Currency / Unit": "iso4217:USD",
"End character": 247,
"End date for period": "2022-11-30",
"Label": "us-gaap:Depreciation",
"Start character": 241,
"Start date for period": "2022-06-01",
"Value": 19591
},
{
"Currency / Unit": "iso4217:USD",
"End character": 260,
"End date for period": "2021-11-30",
"Label": "us-gaap:Depreciation",
"Start character": 253,
"Start date for period": "2021-06-01",
"Value": 165653
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
December 10, 2021, the Company entered into a related party transaction with Jed Kaplan, the Company’s then Chairman of the Board
and a more than 5% shareholder, to provide a loan to the Company to provide additional operating funds for Simplicity One, the Company’s
majority owned subsidiary. The principal amount of the loan was $247,818. The loan bears interest at a rate of 5% per annum and the entire
amount of the principal and accrued interest was due on June 10, 2022. On June 10, 2022, the loan and accrued interest of $6,178 were
converted into a 17% equity stake in Simplicity One, increasing Kaplan’s total stake to 37% and reducing the Company’s stake
to 59%. For the three and six months ended November 30, 2022, the Company recorded interest expense of $0 and $339, respectively, with
no similar expense in the prior periods (Note 8 - Debt). | [
{
"Currency / Unit": "xbrli:pure",
"End character": 382,
"End date for period": "2021-12-10",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 381,
"Start date for period": "2021-12-10",
"Value": 0.05
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | As
of November 30, 2022, and May 31, 2022, the weighted-average remaining lease terms was 3.0 years and 3.6 years, respectively. Due to
the fact that we do not have access to the rate implicit in the lease, we utilized our incremental borrowing rate as the discount rate.
The weighted average discount rate associated with the lease as of November 30, 2022, and May 31, 2022, was 12% and 12%, respectively. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 382,
"End date for period": "2022-11-30",
"Label": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
"Start character": 380,
"Start date for period": "2022-11-30",
"Value": 0.12
},
{
"Currency / Unit": "xbrli:pure",
"End character": 390,
"End date for period": "2022-11-30",
"Label": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
"Start character": 388,
"Start date for period": "2022-11-30",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 29, 2020, (i) the Company entered into an employment agreement (the “Kaplan 2020 Agreement”) with Mr. Kaplan; and (ii)
the Board of Directors approved for Mr. Kaplan a $75,000 cash bonus and authorized the issuance of 250,000 shares of the Company’s
common stock, both related to his performance during the fiscal year ended May 31, 2020. As of November 30, 2022, the Company still owed
Mr. Kaplan $35,000 of the 2020 bonus award. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 413,
"End date for period": "2022-11-30",
"Label": "us-gaap:DueToRelatedPartiesCurrent",
"Start character": 407,
"Start date for period": "2022-11-30",
"Value": 35000
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 29, 2020, (i) the Company entered into an employment agreement (the “Franklin 2020 Agreement”) with Mr. Franklin; and
(ii) the Board of Directors approved for Mr. Franklin a $75,000 cash bonus and authorized the issuance of 250,000 fully vested shares
of the Company’s common stock, both related to his performance during the fiscal year ended May 31, 2020. As of November 30, 2022,
the Company still owed Mr. Franklin $35,000 of the 2020 bonus award. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 189,
"End date for period": "2020-07-29",
"Label": "WINR:CashBonus",
"Start character": 183,
"Start date for period": "2020-07-29",
"Value": 75000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 434,
"End date for period": "2022-11-30",
"Label": "us-gaap:DueToRelatedPartiesCurrent",
"Start character": 428,
"Start date for period": "2022-11-30",
"Value": 35000
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
May 11, 2021, the Board appointed Nancy Hennessey to serve as the Company’s Chief Financial Officer, effective May 17, 2021. In
connection with Ms. Hennessey’s appointment as the Company’s Chief Financial officer, the Company entered into an employment
agreement, dated as of May 17, 2021, by and between the Company and Ms. Hennessey (the “Hennessey Employment Agreement”).
Pursuant to the terms of the Hennessey Employment Agreement, in exchange for Ms. Hennessey’s services, the Company agreed to pay
Ms. Hennessey an annual base salary of $140,000 | [
{
"Currency / Unit": "iso4217:USD",
"End character": 554,
"End date for period": "2021-05-17",
"Label": "us-gaap:OfficersCompensation",
"Start character": 547,
"Start date for period": "2021-05-16",
"Value": 140000
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
February 19, 2021, the Company entered into a securities purchase agreement (the “Labrys SPA”) with Labrys Fund LP (“Labrys”),
an accredited investor, pursuant to which the Company issued a 12% convertible promissory note (the “Labrys Note”) with a
maturity date of February 19, 2022 (the “Labrys Maturity Date”), in the principal sum of $1,650,000. The terms and conditions
of the Labrys Note, as amended, are outlined in the Company’s Annual Report as filed on Form 10-K on September 27, 2022. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 195,
"End date for period": "2021-02-19",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 193,
"Start date for period": "2021-02-19",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | During
the quarter and six months ended November 30, 2022, the Company did not make any payments to Labrys. During the quarter and six months
ended November 30, 2022, the Company recognized $23,277 and $56,949, respectively, in interest expense associated with the Labrys Note
recorded as accrued interest payable. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 209,
"End date for period": "2022-11-30",
"Label": "us-gaap:InterestExpense",
"Start character": 203,
"Start date for period": "2022-06-01",
"Value": 56949
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
March 10, 2021, the Company, entered into a securities purchase agreement (the “March 2021 FirstFire SPA”) with FirstFire
Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire”), pursuant to which the Company issued
a 12% convertible promissory note (“March 2021 FirstFire Note”) with a maturity date of March 10, 2022, in the principal
sum of $560,000. The terms and conditions of the March 2021 FirstFire Note, as amended, are outlined in the Company’s Annual Report
as filed on Form 10-K on September 27, 2022. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 254,
"End date for period": "2021-03-10",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 252,
"Start date for period": "2021-03-10",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
June 11, 2021, the Company entered into a securities purchase agreement (the “June 2021 FirstFire SPA”) with FirstFire, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “June 2021 FirstFire Note”) in the principal sum of
$1,266,666 (the “June 2021 FirstFire Principal Sum”), (ii) 11,875 shares of its common stock as a commitment fee (“June
2021 FirstFire Commitment Shares”), and (iii) a three-year warrant (“June 2021 FirstFire Warrant”) to purchase 593,750
shares of the Company’s common stock at an exercise price of $10.73, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 168,
"End date for period": "2021-06-11",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 166,
"Start date for period": "2021-06-11",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | Upon
issuance of the June 2021 FirstFire Note, the Company received net proceeds of $1,140,000. Upon issuance of the June 2021 FirstFire Commitment
Shares, the June 2021 FirstFire Note, and the June 2021 First Fire Warrant, the Company allocated the $1,140,000 in net proceeds received
between the fair market value of the June 2021 FirstFire Commitment Shares, the beneficial conversion feature of the June 2021 FirstFire
Note, and the June 2021 FirstFire Warrant. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 94,
"End date for period": "2021-06-11",
"Label": "us-gaap:ProceedsFromIssuanceOfDebt",
"Start character": 85,
"Start date for period": "2021-06-10",
"Value": 1140000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 260,
"End date for period": "2021-06-11",
"Label": "us-gaap:ProceedsFromIssuanceOfDebt",
"Start character": 251,
"Start date for period": "2021-06-10",
"Value": 1140000
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | During
the quarter and six months ended November 30, 2022, the Company recorded interest expense of $136,085 and $273,664, respectively, which
was related to the accretion of the debt discount. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 108,
"End date for period": "2022-11-30",
"Label": "us-gaap:InterestExpense",
"Start character": 101,
"Start date for period": "2022-09-01",
"Value": 136085
},
{
"Currency / Unit": "iso4217:USD",
"End character": 121,
"End date for period": "2022-11-30",
"Label": "us-gaap:InterestExpense",
"Start character": 114,
"Start date for period": "2022-06-01",
"Value": 273664
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
June 16, 2021, the Company entered into a securities purchase agreement (the “June 2021 GS SPA”) with GS Capital Partners,
LLC (“GS”), pursuant to which the Company issued (i) a 12% convertible promissory note (the “June 2021 GS Note”)
in the principal sum of $333,333 (the “June 2021 GS Principal Sum”), (ii) 3,125 shares of its common stock as a commitment
fee (“June 2021 GS Commitment Shares”), and (iii) a three-year warrant (“June 2021 GS Warrant”) to purchase 156,250
shares of the Company’s common stock at an exercise price of $10.73, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 183,
"End date for period": "2021-06-16",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 181,
"Start date for period": "2021-06-16",
"Value": 0.12
},
{
"Currency / Unit": "iso4217:USD",
"End character": 271,
"End date for period": "2021-06-16",
"Label": "us-gaap:DebtInstrumentFaceAmount",
"Start character": 264,
"Start date for period": "2021-06-16",
"Value": 333333
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | As
of November 30, 2022, the carrying value of the June 2021 GS Note was $169,507, net of $60,492 in unaccreted debt discount. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 81,
"End date for period": "2022-11-30",
"Label": "us-gaap:DebtInstrumentCarryingAmount",
"Start character": 74,
"Start date for period": "2022-11-30",
"Value": 169507
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
August 23, 2021, the Company entered into a securities purchase agreement (the “August 2021 Jefferson SPA”) with Jefferson
Street Capital, LLC (“Jefferson”), pursuant to which the Company issued (i) a 12% convertible promissory note (the “August
2021 Jefferson Note”) in the principal sum of $333,333 (the “August 2021 Jefferson Principal Sum”), (ii) 3,125 shares
of its common stock as a commitment fee (“August 2021 Jefferson Commitment Shares”), and (iii) a three-year warrant (“August
2021 Jefferson Warrant”) to purchase 156,250 shares of the Company’s common stock at an exercise price of $10.73, subject
to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 206,
"End date for period": "2021-08-23",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 204,
"Start date for period": "2021-08-23",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
August 31, 2021, the Company entered into a securities purchase agreement (the “August 2021 Lucas SPA”) with Lucas Ventures,
LLC (“Lucas”), pursuant to which the Company issued (i) a 12% convertible promissory note (the “August 2021 Lucas Note”)
in the principal sum of $200,000 (the “August 2021 Lucas Principal Sum”), (ii) 3,749 shares of its common stock as a commitment
fee (“August 2021 Lucas Commitment Shares”), and (iii) a three-year warrant (“August 2021 Lucas Warrant”) to
purchase 187,400 shares of the Company’s common stock at an exercise price of $10.22, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 188,
"End date for period": "2021-08-31",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 186,
"Start date for period": "2021-08-31",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
August 31, 2021, the Company and LGH Investments, LLC, (“LGH”) entered into a securities purchase agreement (the “August
2021 LGH SPA”) pursuant to which the Company issued a 12% convertible promissory note (the “August 2021 LGH Note”)
in the principal sum of $200,000 (the “August 2021 LGH Principal Sum”). | [
{
"Currency / Unit": "xbrli:pure",
"End character": 180,
"End date for period": "2021-08-31",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 178,
"Start date for period": "2021-08-31",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 28, 2021, the Company entered into a securities purchase agreement (the “September 2021 Ionic SPA”) with Ionic
Ventures, LLC (“Ionic”), pursuant to which the Company issued (i) a 12% convertible promissory note (the “September
2021 Ionic Note”) in the principal sum of $1,555,556 (the “September 2021 Ionic Principal Sum”), (ii) 14,584 shares
of its common stock as a commitment fee (“September 2021 Ionic Commitment Shares”), and (iii) a three-year warrant (“September
2021 Ionic Warrant”) to purchase 729,167 shares of the Company’s common stock at an exercise price of $10.73, subject to
certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 194,
"End date for period": "2021-09-28",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 192,
"Start date for period": "2021-09-28",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
March 21, 2022, the Company entered into a securities purchase agreement (the “March 2022 FirstFire SPA”) with FirstFire,
pursuant to which the Company issued (i) a 12% convertible promissory note (the “March 2022 FirstFire Note”) in the principal
sum of $110,000 (the “March 2022 FirstFire Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“March
2022 FirstFire Commitment Shares”), and (iii) a three-year warrant (“March 2022 FirstFire Warrant”) to purchase 50,000
shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 170,
"End date for period": "2022-03-21",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 168,
"Start date for period": "2022-03-21",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
March 21, 2022, the Company entered into a securities purchase agreement (the “March 2022 GS SPA”) with GS, pursuant to which
the Company issued (i) a 12% convertible promissory note (the “March 2022 GS Note”) in the principal sum of $82,500 (the
“March 2022 GS Principal Sum”), (ii) 703 shares of its common stock as a commitment fee (“March 2022 GS Commitment
Shares”), and (iii) a three-year warrant (“March 2022 GS Warrant”) to purchase 37,500 shares of the Company’s
common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 156,
"End date for period": "2022-03-21",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 154,
"Start date for period": "2022-03-21",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
March 21, 2022, the Company entered into a securities purchase agreement (the “March 2022 Ionic SPA”) with Ionic, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “March 2022 Ionic Note”) in the principal sum of $110,000
(the “March 2022 Ionic Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“March 2022 Ionic
Commitment Shares”), and (iii) a three-year warrant (“March 2022 Ionic Warrant”) to purchase 50,000 shares of the Company’s
common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 162,
"End date for period": "2022-03-21",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 160,
"Start date for period": "2022-03-21",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
April 1, 2022, the Company entered into a securities purchase agreement (the “April 2022 Jefferson SPA”) with Jefferson,
pursuant to which the Company issued (i) a 12% convertible promissory note (the “April 2022 Jefferson Note”) in the principal
sum of $82,500 (the “April 2022 Jefferson Principal Sum”), (ii) 703 shares of its common stock as a commitment fee (“April
2022 Jefferson Commitment Shares”), and (iii) a three-year warrant (“April 2022 Jefferson Warrant”) to purchase 37,500
shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 169,
"End date for period": "2022-04-02",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 167,
"Start date for period": "2022-04-02",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 14, 2022, the Company entered into a securities purchase agreement (the “July 2022 FirstFire SPA”) with FirstFire, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “July 2022 FirstFire Note”) in the principal sum of
$27,500 (the “July 2022 FirstFire Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“July 2022
FirstFire Commitment Shares”), and (iii) a three-year warrant (“July 2022 FirstFire Warrant”) to purchase 50,000 shares
of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 168,
"End date for period": "2022-07-14",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 166,
"Start date for period": "2022-07-14",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 14, 2022, the Company entered into a securities purchase agreement (the “July 2022 GS SPA”) with GS, pursuant to which
the Company issued (i) a 12% convertible promissory note (the “July 2022 GS Note”) in the principal sum of $27,500 (the “July
2022 GS Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“July 2022 GS Commitment Shares”),
and (iii) a three-year warrant (“July 2022 GS Warrant”) to purchase 50,000 shares of the Company’s common stock at
an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 154,
"End date for period": "2022-07-14",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 152,
"Start date for period": "2022-07-14",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 14, 2022, the Company entered into a securities purchase agreement (the “July 2022 Ionic SPA”) with Ionic, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “July 2022 Ionic Note”) in the principal sum of $27,500
(the “July 2022 Ionic Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“July 2022 Ionic Commitment
Shares”), and (iii) a three-year warrant (“July 2022 Ionic Warrant”) to purchase 50,000 shares of the Company’s
common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 160,
"End date for period": "2022-07-14",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 158,
"Start date for period": "2022-07-14",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
July 14, 2022, the Company entered into a securities purchase agreement (the “July 2022 Jefferson SPA”) with Jefferson, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “July 2022 Jefferson Note”) in the principal sum of
$27,500 (the “July 2022 Jefferson Principal Sum”), (ii) 935 shares of its common stock as a commitment fee (“July 2022
Jefferson Commitment Shares”), and (iii) a three-year warrant (“July 2022 Jefferson Warrant”) to purchase 50,000 shares
of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 168,
"End date for period": "2022-07-14",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 166,
"Start date for period": "2022-07-14",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 8, 2022, the Company entered into a securities purchase agreement (the “September 2022 FirstFire SPA”) with FirstFire,
pursuant to which the Company issued (i) a 12% convertible promissory note (the “September 2022 FirstFire Note”) in the principal
sum of $66,000 (the “September 2022 FirstFire Principal Sum”) and (ii) a three-year warrant (“September 2022 FirstFire
Warrant”) to purchase 120,000 shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 177,
"End date for period": "2022-09-08",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 175,
"Start date for period": "2022-09-08",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 8, 2022, the Company entered into a securities purchase agreement (the “September 2022 Ionic SPA”) with Ionic,
pursuant to which the Company issued (i) a 12% convertible promissory note (the “September 2022 Ionic Note”) in the principal
sum of $66,000 (the “September 2022 Ionic Principal Sum”) and (ii) a three-year warrant (“September 2022 Ionic Warrant”)
to purchase 120,000 shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 169,
"End date for period": "2022-09-08",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 167,
"Start date for period": "2022-09-08",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 8, 2022, the Company entered into a securities purchase agreement (the “September 2022 Jefferson SPA”) with Jefferson,
pursuant to which the Company issued (i) a 12% convertible promissory note (the “September 2022 Jefferson Note”) in the principal
sum of $27,500 (the “September 2022 Jefferson Principal Sum”) and (ii) a three-year warrant (“September 2022 Jefferson
Warrant”) to purchase 45,454 shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 177,
"End date for period": "2022-09-08",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 175,
"Start date for period": "2022-09-08",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 13, 2022, the Company entered into a securities purchase agreement (the “September 2022 GS SPA”) with GS, pursuant
to which the Company issued (i) a 12% convertible promissory note (the “September 2022 GS Note”) in the principal sum of
$11,000 (the “September 2022 GS Principal Sum”) and (ii) a three-year warrant (“September 2022 GS Warrant”) to
purchase 18,000 shares of the Company’s common stock at an exercise price of $1.00, subject to certain adjustments. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 164,
"End date for period": "2022-09-13",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 162,
"Start date for period": "2022-09-13",
"Value": 0.12
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
November 15, 2021, the Company entered into a 10% secured promissory note with an accredited investor (“Secured Note One”)
for which it received net proceeds of $250,000, consisting of a face amount of $262,500 and an original issuance discount of $12,500
“(Secured Note One OID”). In addition, the Company issued 30,000 commitment warrants to the investor for the purchase of
the Company’s common stock at an exercise price of $10.73 per share (“Secured Note One Warrants”). | [
{
"Currency / Unit": "xbrli:pure",
"End character": 51,
"End date for period": "2021-11-15",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 49,
"Start date for period": "2021-11-15",
"Value": 0.1
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
November 18, 2021, the Company entered into a 10% secured promissory note with an accredited investor (“Secured Note Two”)
for which it received net proceeds of $150,000, consisting of a face amount of $157,500 and an original issuance discount of $7,500 (“Secured
Note Two OID”). In addition, the Company issued 18,000 commitment warrants for the purchase of the Company’s common stock
at an exercise price of $10.73 per share (“Secured Note Two Warrant”). | [
{
"Currency / Unit": "xbrli:pure",
"End character": 51,
"End date for period": "2022-11-18",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 49,
"Start date for period": "2022-11-18",
"Value": 0.1
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
December 10, 2021, the Company entered into a loan agreement with Jed Kaplan, the Company’s former Chairman of the Board, that
has a principal amount of $247,818 (See Note 6 - Related Party Transactions). The loan bears interest at a rate of 5% per annum and matured
on June 10, 2022. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 246,
"End date for period": "2021-12-10",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 245,
"Start date for period": "2021-12-10",
"Value": 0.05
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | During
the quarter and six months ended November 30, 2022, the Company issued 303,454 and 503,454 warrants, respectively, to acquire shares
of Common Stock to accredited investors in association with issued debt instruments (See Note 8 – Debt). Upon issuance, the fair
value of these warrants was estimated at the date of issuance using the Black-Scholes option-pricing model with the following assumptions:
(i) exercise price of $1.00 per share; (ii) expected dividend yield of 0%; (iii) expected volatility of 134% to 147%; (iv) risk-free
interest rates of 3.16% - 3.75%; and (v) term of 3.0 years. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 480,
"End date for period": "2022-11-30",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"Start character": 479,
"Start date for period": "2022-06-01",
"Value": 0
},
{
"Currency / Unit": "xbrli:pure",
"End character": 515,
"End date for period": "2022-11-30",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"Start character": 512,
"Start date for period": "2022-06-01",
"Value": 1.34
},
{
"Currency / Unit": "xbrli:pure",
"End character": 523,
"End date for period": "2022-11-30",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"Start character": 520,
"Start date for period": "2022-06-01",
"Value": 1.47
},
{
"Currency / Unit": "xbrli:pure",
"End character": 563,
"End date for period": "2022-11-30",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"Start character": 559,
"Start date for period": "2022-06-01",
"Value": 0.0316
},
{
"Currency / Unit": "xbrli:pure",
"End character": 571,
"End date for period": "2022-11-30",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"Start character": 567,
"Start date for period": "2022-06-01",
"Value": 0.0375
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
September 28, 2022, the Company entered into an exchange agreement (the “Exchange Agreement”), dated as of September 28,
2022, by and among the Company, Diverted River Technology, LLC (“Diverted River”), the member(s) of Diverted River from time
to time (the “Members”) and Zachary Johnson, as the Members’ representative. Pursuant to the terms of the Exchange
Agreement, the Company agreed to acquire from the Members 100% of the membership interests of Diverted River held by the Members as of
the closing (the “Closing”), in exchange for the issuance by the Company to the Members of shares of the Company’s
common stock equal to 80% of the issued and outstanding shares of the Company’s common stock as of the Closing. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 425,
"End date for period": "2022-09-28",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 422,
"Start date for period": "2022-09-28",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 638,
"End date for period": "2022-09-28",
"Label": "WINR:PercentageOfIssuedAndOutstanding",
"Start character": 636,
"Start date for period": "2022-09-25",
"Value": 0.8
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | The
Exchange Agreement contains certain covenants, representations and warranties customary for an agreement of this type. In addition, the
Closing is subject to the satisfaction or waiver of certain conditions, including, but not limited to, (i) the increase by the Company
of its authorized shares of common stock to 250,000,000 shares; (ii) execution by Diverted River of agreements with clients generating
at least $60,000 per month in revenue for at least 24 months following the Closing, with such agreements being in form and substance
as agreed to by the Company and Diverted River; (iii) settlement by the Company of any debt with landlords related to the closure of
the Company’s gaming center venues; (iv) the Company having obtained binding commitments from investors to invest at least $4,000,000,
through the issuance of shares of Company common stock; (v) repayment by the Company of its convertible notes, or execution of agreements
with noteholders to convert such notes into shares of Company common stock comprising no more than 12.5% of the issued and outstanding
common stock of the Company after giving effect to the Closing; (vi) reaching an agreement with warrant holders to amend the exercise
price to be $1.00 per share; (vii) execution of note amendments by holders of Company promissory notes that are not presently convertible
into shares of Company common stock such that the notes will be converted into Company common stock and such notes shall have been converted,
with such shares being included in the 12.5% limitation set forth in clause (v) hereof; (viii) provision by Diverted River of audited
financial statements; and (ix) completion of satisfactory due diligence reviews by the Company and Diverted River. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 1052,
"End date for period": "2022-09-28",
"Label": "WINR:PercentageOfIssuedAndOutstanding",
"Start character": 1048,
"Start date for period": "2022-09-25",
"Value": 0.125
},
{
"Currency / Unit": "xbrli:pure",
"End character": 1541,
"End date for period": "2022-09-28",
"Label": "WINR:PercentageOfIssuedAndOutstanding",
"Start character": 1537,
"Start date for period": "2022-09-25",
"Value": 0.125
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
January 30, 2023, the Company entered into a securities purchase agreement (the “2023 Ionic SPA”), dated as of January 30,
2023, with Ionic Ventures, LLC (“Ionic”), pursuant to which the Company issued a 12% promissory convertible note (the “2023
Ionic Note”) with a maturity date of May 30, 2023, in the principal sum of $35,200. Pursuant to the terms of the 2023 Ionic Note,
the Company agreed to pay to Ionic $35,200 and to pay interest on the principal balance at the rate of 12% per annum. The 2023 Ionic
Note carries an original issue discount of $3,200. Accordingly, Ionic paid the purchase price of $32,000 in exchange for the 2023 Ionic
Note. The Company intends to use the proceeds for working capital. Ionic may convert the 2023 Ionic Note into the Company’s Common
Stock (subject to the beneficial ownership limitations of 4.99% in the 2023 Ionic Note; provided however, that the limitation on conversion
may be waived (up to 9.99%) by Ionic upon, at the election of Ionic, not less than 61 days’ prior notice to the Company) at any
time at a conversion price equal to $0.0175 per share, as the same may be adjusted as provided in the 2023 Ionic Note. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 209,
"End date for period": "2023-01-30",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 207,
"Start date for period": "2023-01-30",
"Value": 0.12
},
{
"Currency / Unit": "xbrli:pure",
"End character": 485,
"End date for period": "2023-01-30",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 483,
"Start date for period": "2023-01-30",
"Value": 0.12
},
{
"Currency / Unit": "xbrli:pure",
"End character": 842,
"End date for period": "2023-01-30",
"Label": "WINR:PercentageOfBeneficialOwnershipLimitations",
"Start character": 838,
"Start date for period": "2023-01-30",
"Value": 0.0499
},
{
"Currency / Unit": "xbrli:pure",
"End character": 945,
"End date for period": "2023-01-30",
"Label": "WINR:PercentageOfBeneficialOwnershipLimitations",
"Start character": 941,
"Start date for period": "2023-01-30",
"Value": 0.0999
}
] |
10-Q | 0001493152-23-007159 | 20230310060458 | 20221130 | SIMPLICITY ESPORTS & GAMING Co | On
January 30, 2023, the Company entered into a securities purchase agreement (the “2023 FirstFire SPA”), dated as of January
30, 2023, with FirstFire Global Opportunities Fund, LLC (“FirstFire”), pursuant to which the Company issued a 12% promissory
convertible note (the “2023 FirstFire Note”) with a maturity date of May 30, 2023, in the principal sum of $35,200. Pursuant
to the terms of the 2023 FirstFire Note, the Company agreed to pay to FirstFire $35,200 and to pay interest on the principal balance
at the rate of 12% per annum. The 2023 FirstFire Note carries an original issue discount of $3,200. Accordingly, FirstFire paid the purchase
price of $32,000 in exchange for the 2023 FirstFire Note. The Company intends to use the proceeds for working capital. FirstFire may
convert the 2023 FirstFire Note into the Company’s Common Stock (subject to the beneficial ownership limitations of 4.99% in the
2023 FirstFire Note; provided however, that the limitation on conversion may be waived (up to 9.99%) by FirstFire upon, at the election
of FirstFire, not less than 61 days’ prior notice to the Company) at any time at a conversion price equal to $0.0175 per share,
as the same may be adjusted as provided in the 2023 FirstFire Note. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 365,
"End date for period": "2023-01-30",
"Label": "us-gaap:DebtInstrumentFaceAmount",
"Start character": 359,
"Start date for period": "2023-01-30",
"Value": 35200
},
{
"Currency / Unit": "iso4217:USD",
"End character": 463,
"End date for period": "2023-01-30",
"Label": "us-gaap:DebtInstrumentFaceAmount",
"Start character": 457,
"Start date for period": "2023-01-30",
"Value": 35200
},
{
"Currency / Unit": "xbrli:pure",
"End character": 526,
"End date for period": "2023-01-30",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 524,
"Start date for period": "2023-01-30",
"Value": 0.12
},
{
"Currency / Unit": "iso4217:USD",
"End character": 607,
"End date for period": "2023-01-30",
"Label": "us-gaap:AmortizationOfDebtDiscountPremium",
"Start character": 602,
"Start date for period": "2023-01-28",
"Value": 3200
},
{
"Currency / Unit": "xbrli:pure",
"End character": 903,
"End date for period": "2023-01-30",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 899,
"Start date for period": "2023-01-30",
"Value": 0.0499
},
{
"Currency / Unit": "xbrli:pure",
"End character": 1010,
"End date for period": "2023-01-30",
"Label": "WINR:PercentageOfBeneficialOwnershipLimitations",
"Start character": 1006,
"Start date for period": "2023-01-30",
"Value": 0.0999
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | We have foreign currency cash accounts to operate our global business. These accounts are impacted by changes in foreign currency rates. Of our $10,022 in cash and cash equivalents balances at January 28, 2023, $3,257 were denominated in U.S. dollars, of which $498 were held by our foreign subsidiaries. As of January 28, 2023, we had an additional $6,765 in cash balances denominated in foreign currencies, of which $5,421 were maintained in accounts of our foreign subsidiaries. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 151,
"End date for period": "2023-01-28",
"Label": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"Start character": 145,
"Start date for period": "2023-01-28",
"Value": 10022000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 217,
"End date for period": "2023-01-28",
"Label": "us-gaap-supplement:CashNotHeldInForeignCurrency",
"Start character": 212,
"Start date for period": "2023-01-28",
"Value": 3257000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 265,
"End date for period": "2023-01-28",
"Label": "us-gaap-supplement:CashHeldInForeignCurrency",
"Start character": 262,
"Start date for period": "2023-01-28",
"Value": 498000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 356,
"End date for period": "2023-01-28",
"Label": "dakt:CashAdditionalAmountHeldInForeignCurrency",
"Start character": 351,
"Start date for period": "2023-01-28",
"Value": 6765000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 424,
"End date for period": "2023-01-28",
"Label": "dakt:CashAdditionalAmountHeldInForeignCurrenciesMaintainedByForeignSubsidiaries",
"Start character": 419,
"Start date for period": "2023-01-28",
"Value": 5421000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | During much of the past calendar year, we have experienced negative impacts in our business driven by global economic conditions and supply chain disruptions. These conditions have caused volatility in our cash flow, pricing, order volumes, lead-times, competitiveness, revenue cycles, and production costs. To adapt, we used cash and line of credit borrowings to increase our investment in inventory to add stability to our production processes to fulfill backlog and used cash to invest in property and equipment to expand our capacity and add automation. To improve operations and cash flows, we have increased prices of our goods and services. In addition, we instituted a liquidity enhancement plan program focusing our teams on improving our cash flow and enhancing our liquidity. Our ability to fund inventory levels, operations, and capital expenditures in the future will be dependent on our ability to generate cash flow from operations in these conditions, to maintain or improve margins, and to use funds from our credit facility. $35,000 of our credit facility expires in April 2025 and $10,000 expires in May 2023, and it requires us to comply with certain covenants. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 1050,
"End date for period": "2025-04-30",
"Label": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
"Start character": 1044,
"Start date for period": "2025-04-30",
"Value": 35000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 1107,
"End date for period": "2023-05-31",
"Label": "dakt:LineOfCreditFacilityAccordionFeatureIncreaseLimit",
"Start character": 1101,
"Start date for period": "2023-05-31",
"Value": 10000000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | The aggregate amount of our investments accounted for under the equity method was $17,145 and $16,916 as of January 28, 2023 and April 30, 2022, respectively. Our proportional share of the respective affiliates' earnings or losses is included in the "Other expense, net" line item in our condensed consolidated statements of operations. For the three and nine months ended January 28, 2023, our share of the losses of our affiliates was $895 and $2,596 as compared to $401 and $1,966 for the three and nine months ended January 29, 2022. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 89,
"End date for period": "2023-01-28",
"Label": "us-gaap:EquityMethodInvestments",
"Start character": 83,
"Start date for period": "2023-01-28",
"Value": 17145000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 101,
"End date for period": "2022-04-30",
"Label": "us-gaap:EquityMethodInvestments",
"Start character": 95,
"Start date for period": "2022-04-30",
"Value": 16916000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 441,
"End date for period": "2023-01-28",
"Label": "us-gaap:IncomeLossFromEquityMethodInvestments",
"Start character": 438,
"Start date for period": "2022-10-30",
"Value": -895000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 452,
"End date for period": "2023-01-28",
"Label": "us-gaap:IncomeLossFromEquityMethodInvestments",
"Start character": 447,
"Start date for period": "2022-05-01",
"Value": -2596000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 472,
"End date for period": "2022-01-29",
"Label": "us-gaap:IncomeLossFromEquityMethodInvestments",
"Start character": 469,
"Start date for period": "2021-10-31",
"Value": -401000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 483,
"End date for period": "2022-01-29",
"Label": "us-gaap:IncomeLossFromEquityMethodInvestments",
"Start character": 478,
"Start date for period": "2021-05-02",
"Value": -1966000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | We purchased services for research and development activities from our equity method investees. The total of these related party transactions for the nine months ended January 28, 2023 and January 29, 2022 was $672 and $1,520, respectively, which is included in the "Product design and development" line item in our condensed consolidated statements of operations, and for the nine months ended January 28, 2023, $52 remains unpaid and is included in the "Accounts payable" line item in our condensed consolidated balance sheets. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 214,
"End date for period": "2023-01-28",
"Label": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
"Start character": 211,
"Start date for period": "2022-10-30",
"Value": 672000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 225,
"End date for period": "2022-01-29",
"Label": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
"Start character": 220,
"Start date for period": "2021-10-31",
"Value": 1520000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 416,
"End date for period": "2023-01-28",
"Label": "us-gaap:AccountsPayableCurrentAndNoncurrent",
"Start character": 414,
"Start date for period": "2023-01-28",
"Value": 52000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | During the nine months ended January 28, 2023, we invested $2,250 evidenced by convertible notes and $990 evidenced by promissory notes ("Notes") in our affiliates, which is included in the "Investment in affiliates and other assets" line item in our condensed consolidated balance sheets. During the nine months ended January 28, 2023, we converted $2,823 evidenced by the Notes to stock ownership. After this conversion of Notes to stock ownership, our ownership increased to | [
{
"Currency / Unit": "iso4217:USD",
"End character": 65,
"End date for period": "2023-01-28",
"Label": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
"Start character": 60,
"Start date for period": "2022-05-01",
"Value": 2250000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 105,
"End date for period": "2023-01-28",
"Label": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
"Start character": 102,
"Start date for period": "2022-05-01",
"Value": 990000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 356,
"End date for period": "2023-01-28",
"Label": "us-gaap:DebtConversionConvertedInstrumentAmount1",
"Start character": 351,
"Start date for period": "2022-05-01",
"Value": 2823000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | Options outstanding to purchase 2,102 shares of common stock with a weighted average exercise price of $7.13 for the three months ended January 28, 2023 and 2,216 shares of common stock with a weighted average exercise price of $8.17 for the three months ended January 29, 2022 were not included in the computation of diluted earnings per share because the effects would be anti-dilutive. | [
{
"Currency / Unit": "xbrli:shares",
"End character": 37,
"End date for period": "2023-01-28",
"Label": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"Start character": 32,
"Start date for period": "2022-10-30",
"Value": 2102000
},
{
"Currency / Unit": null,
"End character": 108,
"End date for period": "2023-01-28",
"Label": "dakt:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice",
"Start character": 104,
"Start date for period": "2022-10-30",
"Value": 7.13
},
{
"Currency / Unit": "xbrli:shares",
"End character": 162,
"End date for period": "2022-01-29",
"Label": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"Start character": 157,
"Start date for period": "2021-10-31",
"Value": 2216000
},
{
"Currency / Unit": null,
"End character": 233,
"End date for period": "2022-01-29",
"Label": "dakt:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareWeightedAverageExercisePrice",
"Start character": 229,
"Start date for period": "2021-10-31",
"Value": 8.17
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | During the nine months ended January 28, 2023, we recognized revenue of $81,966 related to our contract liabilities as of April 30, 2022. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 79,
"End date for period": "2023-01-28",
"Label": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
"Start character": 73,
"Start date for period": "2022-05-01",
"Value": 81966000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | As of January 28, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations was $491,345. Remaining performance obligations related to product and service agreements at January 28, 2023 were $429,097 and $62,248, respectively. We expect approximately $430,602 of our remaining performance obligations to be recognized over the next 12 months, with the remainder recognized thereafter. Although remaining performance obligations reflect business that is considered to be legally binding, cancellations, deferrals or scope adjustments may occur. Any known project cancellations, revisions to project scope and cost, foreign currency exchange fluctuations, and project deferrals are reflected or excluded in the remaining performance obligation balance, as appropriate. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 133,
"End date for period": "2023-01-28",
"Label": "us-gaap:RevenueRemainingPerformanceObligation",
"Start character": 126,
"Start date for period": "2023-01-28",
"Value": 491345000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 244,
"End date for period": "2023-01-28",
"Label": "us-gaap:RevenueRemainingPerformanceObligation",
"Start character": 237,
"Start date for period": "2023-01-28",
"Value": 429097000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 256,
"End date for period": "2023-01-28",
"Label": "us-gaap:RevenueRemainingPerformanceObligation",
"Start character": 250,
"Start date for period": "2023-01-28",
"Value": 62248000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 304,
"End date for period": "2023-01-28",
"Label": "us-gaap:RevenueRemainingPerformanceObligation",
"Start character": 297,
"Start date for period": "2023-01-28",
"Value": 430602000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | The following table sets forth certain financial information for each of our five reporting segments for the periods indicated: | [
{
"Currency / Unit": "dakt:segment",
"End character": 81,
"End date for period": "2023-01-28",
"Label": "us-gaap:NumberOfReportableSegments",
"Start character": 77,
"Start date for period": "2022-05-01",
"Value": 5
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | determined the fair value of the reporting units based on an income approach, using the present value of future discounted cash flows. Significant estimates used to determine fair value include the weighted average cost of capital and financial forecasts. The recognized impairment was primarily a result of our weighted average cost of capital being notably higher, which was driven by strains on our liquidity caused by disrupted supply chains and geopolitical conditions that have given ongoing logistics challenges to certain large projects. As a result the present value of our future cash flows was lower, which caused the $4,576 impairment charge. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 635,
"End date for period": "2023-01-28",
"Label": "us-gaap:GoodwillImpairmentLoss",
"Start character": 630,
"Start date for period": "2022-10-30",
"Value": 4576000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | under the loan portion of our line of credit, and the balance of letters of credit outstanding was approximately $7,516. As of January 28, 2023, we were in compliance with our financial covenants. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 119,
"End date for period": "2023-01-28",
"Label": "us-gaap:LineOfCredit",
"Start character": 114,
"Start date for period": "2023-01-28",
"Value": 7516000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | As of January 28, 2023, we had $616 of bank guarantees or other financial instruments for display installations issued by another bank and secured by a restricted cash deposit. If we are unable to meet the terms of the arrangement, the bank would subrogate its loss by drawing on the secured cash deposit. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 35,
"End date for period": "2023-01-28",
"Label": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
"Start character": 32,
"Start date for period": "2023-01-28",
"Value": 616000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | We have entered into standby letters of credit, bank guarantees and surety bonds with financial institutions relating to the guarantee of our future performance on contracts, primarily construction-type contracts. As of January 28, 2023, we had outstanding letters of credit, bank guarantees and surety bonds in the amount of $7,516, $616 and $63,312, respectively. Performance guarantees are issued to certain customers to guarantee the operation and installation of the equipment and our ability to complete a contract. These performance guarantees have various terms but are generally one year. We enter into written agreements with our customers, and those agreements often contain indemnification provisions that require us to make the customer whole if certain acts or omissions by us cause the customer financial loss. We make efforts to negotiate reasonable caps and limitations on the recovery of such damages. As of January 28, 2023, we were not aware of any indemnification claim from a customer. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 332,
"End date for period": "2023-01-28",
"Label": "us-gaap:LossContingencyAccrualAtCarryingValue",
"Start character": 327,
"Start date for period": "2023-01-28",
"Value": 7516000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 338,
"End date for period": "2023-01-28",
"Label": "us-gaap:LossContingencyAccrualAtCarryingValue",
"Start character": 335,
"Start date for period": "2023-01-28",
"Value": 616000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 350,
"End date for period": "2023-01-28",
"Label": "us-gaap:LossContingencyAccrualAtCarryingValue",
"Start character": 344,
"Start date for period": "2023-01-28",
"Value": 63312000
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | Our effective tax rate for the three months ended January 28, 2023 was a tax rate of 30.5 percent, as compared to an effective tax rate of 32.2 percent for the three months ended January 29, 2022. For the nine months ended | [
{
"Currency / Unit": "xbrli:pure",
"End character": 89,
"End date for period": "2023-01-28",
"Label": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"Start character": 85,
"Start date for period": "2022-10-30",
"Value": 0.305
},
{
"Currency / Unit": "xbrli:pure",
"End character": 143,
"End date for period": "2022-01-29",
"Label": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"Start character": 139,
"Start date for period": "2021-10-31",
"Value": 0.322
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | recording of a full valuation allowance on deferred tax assets during the second quarter of fiscal 2023 related to GAAP accounting for income taxes and related information. For the nine months ended January 29, 2022, our effective tax was 9.4 percent. See "Note 1. Basis of Presentation - Liquidity and Going Concern" of the Notes to our Condensed Consolidated Financial Statements included in this Report. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 242,
"End date for period": "2022-01-29",
"Label": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"Start character": 239,
"Start date for period": "2021-05-02",
"Value": 0.094
}
] |
10-Q | 0000915779-23-000020 | 20230313114023 | 20230128 | DAKTRONICS INC /SD/ | We operate both domestically and internationally and, as of January 28, 2023, undistributed earnings of our foreign subsidiaries were considered to be reinvested indefinitely. Additionally, as of January 28, 2023, we had $361 of unrecognized tax benefits which would reduce our effective tax rate if recognized. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 225,
"End date for period": "2023-01-28",
"Label": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
"Start character": 222,
"Start date for period": "2023-01-28",
"Value": 361000
}
] |
10-Q | 0001213900-23-020949 | 20230317150029 | 20230131 | ATIF Holdings Ltd | For the three months ended January 31, 2022, one customer
accounted for 100% of the Company’s total revenue. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 48,
"End date for period": "2022-01-31",
"Label": "atif:NumberOfCustomer",
"Start character": 45,
"Start date for period": "2021-11-01",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 75,
"End date for period": "2022-01-31",
"Label": "us-gaap:PublicUtilitiesRequestedReturnOnEquityPercentage",
"Start character": 72,
"Start date for period": "2021-11-01",
"Value": 1
}
] |
10-Q | 0001213900-23-020949 | 20230317150029 | 20230131 | ATIF Holdings Ltd | For the
six months ended January 31, 2022, one customer accounted for 95% of the Company’s total revenue. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 46,
"End date for period": "2022-01-31",
"Label": "atif:NumberOfCustomer",
"Start character": 43,
"Start date for period": "2021-08-01",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 72,
"End date for period": "2022-01-31",
"Label": "us-gaap:PublicUtilitiesRequestedReturnOnEquityPercentage",
"Start character": 70,
"Start date for period": "2021-08-01",
"Value": 0.9500000000000001
}
] |
10-Q | 0001493152-23-005657 | 20230221161912 | 20221231 | GLOBAL TECHNOLOGIES LTD | Investments
having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the
periods presented, the Company had no cash equivalents. The Company has cash on deposit at one financial institution which, at times,
may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses
in such accounts and periodically evaluates the creditworthiness of its financial institutions. In the future, the Company may reduce
its credit risk by placing its cash and cash equivalents with major financial institutions. The Company had approximately $69 of
cash and cash equivalents at December 31, 2022 of which none was held in foreign bank accounts and $0 was not covered by FDIC insurance
limits as of December 31, 2022. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 182,
"End date for period": "2022-12-31",
"Label": "us-gaap:CashEquivalentsAtCarryingValue",
"Start character": 180,
"Start date for period": "2022-12-31",
"Value": 0
}
] |
10-Q | 0001493152-23-005657 | 20230221161912 | 20221231 | GLOBAL TECHNOLOGIES LTD | Concentration
of Notes Receivable – The Company had notes receivable of $350,000 and $350,000 at December 31, 2022 and
June 30, 2022, respectively. At December 31, 2022, one borrower accounted for 100% of the Company’s total notes
receivable. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 200,
"End date for period": "2022-12-31",
"Label": "us-gaap:ConcentrationRiskPercentage1",
"Start character": 197,
"Start date for period": "2022-07-01",
"Value": 1
}
] |
10-Q | 0001493152-23-005657 | 20230221161912 | 20221231 | GLOBAL TECHNOLOGIES LTD | On
November 30, 2019, the Company acquired 100% ownership of TCBM Holdings, LLC (“TCBM”) and TCBM’s two wholly owned subsidiaries,
HMNRTH, LLC and 911 Help Now, LLC. The combination has been accounted for in the accompanying consolidated financial statements as an
“acquisition” transaction. Accordingly, the financial position and results of operation of the Company prior to November
30, 2019 has been excluded from the accompanying consolidated financial statements. The Company acquired a 100% interest in exchange
for a Convertible Promissory Note in the amount of $2,000,000. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 46,
"End date for period": "2019-11-30",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 43,
"Start date for period": "2019-11-30",
"Value": 1
},
{
"Currency / Unit": "iso4217:USD",
"End character": 580,
"End date for period": "2019-11-30",
"Label": "us-gaap:ConvertibleNotesPayable",
"Start character": 571,
"Start date for period": "2019-11-30",
"Value": 2000000
}
] |
10-Q | 0001493152-23-005657 | 20230221161912 | 20221231 | GLOBAL TECHNOLOGIES LTD | On
November 17, 2021, the Company issued 126,674,824 shares of common stock with a fair market value of $456,029 for a cashless exercise
of a warrant. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 112,
"End date for period": "2021-11-17",
"Label": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
"Start character": 105,
"Start date for period": "2021-11-16",
"Value": 456029
}
] |
10-Q | 0001493152-23-005657 | 20230221161912 | 20221231 | GLOBAL TECHNOLOGIES LTD | In
performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to
meet our financial obligations as they become due. We have a history of net losses: As of December 31, 2022, we had an accumulated deficit
of $166,320,069. For the six months ended December 31, 2022, we had cash used in operating activities of $324,425. We expect to continue
to incur negative cash flows until such time as our operating segments generate sufficient cash inflows to finance our operations and
debt service requirements. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 291,
"End date for period": "2022-12-31",
"Label": "us-gaap:RetainedEarningsAccumulatedDeficit",
"Start character": 280,
"Start date for period": "2022-12-31",
"Value": -166320069
},
{
"Currency / Unit": "iso4217:USD",
"End character": 389,
"End date for period": "2022-12-31",
"Label": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
"Start character": 382,
"Start date for period": "2022-07-01",
"Value": -324425
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | The
Company’s wholly-owned Australian subsidiary incurs research and development expenses, primarily in the course of conducting clinical
trials. The Company’s Australian research and development activities qualify for the Australian government’s tax credit program,
which provides a 48.5% credit for qualifying research and development expenses. The tax credit does not depend on the Company’s
generation of future taxable income or ongoing tax status or position. Accordingly, the credit is not considered an element of income
tax accounting under ASC 740 “Income Taxes” and is recorded against qualifying research and development expenses. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 288,
"End date for period": "2023-01-31",
"Label": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits",
"Start character": 284,
"Start date for period": "2022-08-01",
"Value": 0.485
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | The
Company has sustained losses in all reporting periods since inception, with an accumulated deficit of approximately $301 million as of
January 31, 2023. These losses are expected to continue for an extended period of time. Further, the Company has never generated any
cash from its operations and does not expect to generate such cash in the near term. The aforementioned factors raise substantial doubt
about the Company’s ability to continue as a going concern within one year from the issuance date of the condensed consolidated
financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which
contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated
financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification
of liabilities that might be necessary should the Company be unable to continue as a going concern within one year after the date the
condensed consolidated financial statements are issued. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 124,
"End date for period": "2023-01-31",
"Label": "us-gaap:RetainedEarningsAccumulatedDeficit",
"Start character": 121,
"Start date for period": "2023-01-31",
"Value": -301000000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | As
of March 6, 2023, the Company had cash and cash equivalents of $2.0 million. Since inception, cash flows from financing activities have
been the primary source of the Company’s liquidity. Based on the Company’s current cash levels, the Company believes its
cash resources are insufficient to meet the Company’s anticipated needs for the 12 months following the date the condensed consolidated
financial statements are issued. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 70,
"End date for period": "2023-03-06",
"Label": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"Start character": 67,
"Start date for period": "2023-03-06",
"Value": 2000000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | On
July 11, 2022, the Company entered into a finance agreement with AFCO Premium Credit LLC (“AFCO”). Pursuant to the terms
of the agreement, AFCO loaned the Company the principal amount of $1,027,986, which would accrue interest at 5.248% per annum, to partially
fund the payment of the premium of the Company’s Director & Officer insurance. The agreement requires the Company to make eleven
monthly payments of $95,923, including interest starting on July 18, 2022. At January 31, 2023 and July 31, 2022, the outstanding balance
related to this finance agreement was $379,535 and $936,558, respectively. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 238,
"End date for period": "2022-07-11",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 233,
"Start date for period": "2022-07-11",
"Value": 0.052480000000000006
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Pre-Funded Warrants were exercised on December
1, 2022. The terms and conditions of the Warrants are as noted and governed by the agreements entered into with the holders on December
1, 2022. Placement agent fees and other offering expenses of approximately $0.7
| [
{
"Currency / Unit": "iso4217:USD",
"End character": 262,
"End date for period": "2020-08-19",
"Label": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
"Start character": 259,
"Start date for period": "2020-08-18",
"Value": 700000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | million incurred directly related to the offering
were reflected as a reduction in additional paid in capital. Total proceeds were allocated between the Shares and Warrants on a relative
fair value basis given both securities are equity classified. The fair value of the Common Warrants issued to the Investors in the offering
was approximately $1.5 million (based on a Monte Carlo simulation assuming no dividend yield, a 5.0 year life, a risk-free interest rate
of 3.61% and volatilities of 92.3% or 100% varying based on the trigger of a fundamental transaction). | [
{
"Currency / Unit": "iso4217:USD",
"End character": 349,
"End date for period": "2022-12-01",
"Label": "us-gaap:WarrantsAndRightsOutstanding",
"Start character": 346,
"Start date for period": "2022-12-01",
"Value": 1500000
},
{
"Currency / Unit": "xbrli:pure",
"End character": 505,
"End date for period": "2022-12-01",
"Label": "ONCS:VaryingBasedOnTriggerOfFundamentalTransactionPercentage",
"Start character": 502,
"Start date for period": "2022-12-01",
"Value": 1
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | During
the six months ended January 31, 2023, shares of common stock issued related to the Pre-Funded Warrant exercises totaled 916,667. The
Company realized proceeds of $92 from the Pre-Funded Warrant exercises. There were no warrants exercised during the six months ended
January 31, 2022. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 226,
"End date for period": "2022-01-31",
"Label": "us-gaap:ProceedsFromWarrantExercises",
"Start character": 224,
"Start date for period": "2021-08-01",
"Value": 0
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | On
October 10, 2019, the Company and Grand Decade Developments Limited (“GDDL”), a direct, wholly-owned subsidiary of Grand
Pharmaceutical Group Limited (formerly China Grand Pharmaceutical and Healthcare Holdings Limited), a company formed under the laws of
the British Virgin Islands (“CGP”), and its affiliate, Sirtex Medical US Holdings, Inc., a Delaware corporation (“Sirtex”)
entered into Stock Purchase Agreements (as amended, the “Purchase Agreements”), pursuant to which the Company agreed to sell
and issue to CGP and Sirtex 454,545 shares and 90,909 shares, respectively, of the Company’s common stock for a total purchase
price of $30.0 million. The net proceeds, after deducting offering fees and expenses paid by the Company, were approximately $28.0 million.
This transaction closed on February 7, 2020 (the “Closing”). Pursuant to the Purchase Agreements, CGP and Sirtex were given
the right under certain circumstances to purchase in the future additional shares of common stock in order to maintain CGP and Sirtex’s
respective ownership percentages of the outstanding shares of common stock of the Company as of the Closing. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 648,
"End date for period": "2019-10-10",
"Label": "us-gaap:PaymentsForRepurchaseOfCommonStock",
"Start character": 644,
"Start date for period": "2019-10-09",
"Value": 30000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 764,
"End date for period": "2019-10-10",
"Label": "us-gaap:ProceedsFromIssuanceOfCommonStock",
"Start character": 760,
"Start date for period": "2019-10-09",
"Value": 28000000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | The
OncoSec Medical Incorporated 2011 Stock Incentive Plan (as amended and approved by the Company’s stockholders (the “2011
Plan”)), authorizes the Company’s Board of Directors to grant equity awards, including but not limited to, stock options
and restricted stock units, to employees, directors and consultants. The 2011 Plan authorizes a total of 209,091 shares of common stock
for issuance. Under the 2011 Plan, incentive stock options are to be granted at a price that is no less than 100% of the fair value of
the Company’s common stock at the date of grant. Stock options vest over a period specified in the individual option agreements
entered into with grantees and are exercisable for a maximum period of 10 years after the date of grant. Incentive stock options granted
to stockholders who own more than 10% of the outstanding stock of the Company at the time of grant must be issued at an exercise price
of no less than 110% of the fair value of the Company’s common stock on the date of grant. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 494,
"End date for period": "2023-01-31",
"Label": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
"Start character": 491,
"Start date for period": "2022-08-01",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 936,
"End date for period": "2023-01-31",
"Label": "ONCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockOwnedByStockholders",
"Start character": 933,
"Start date for period": "2022-08-01",
"Value": 1.1
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | As
of January 31, 2023, the Company has approximately $0.3 million in unrecognized stock-based compensation expense attributable to the
outstanding options, which is expected to be recognized over a weighted-average period of 0.39 years. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 58,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 55,
"Start date for period": "2022-08-01",
"Value": 300000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Stock-based
compensation expense recorded in the Company’s condensed consolidated statements of operations for the three and six months ended
January 31, 2023 resulting from stock options awarded to the Company’s employees, directors and consultants was approximately $0.3
million and $0.5 million, respectively. Of the total expense, $0.1 million and $0.2 million, respectively, was recorded to research and
development and $0.2 million and $0.3 million, respectively, was recorded in general and administrative in the Company’s condensed
consolidated statements of operations for the three and six months ended January 31, 2023. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 272,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 269,
"Start date for period": "2022-11-01",
"Value": 300000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 289,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 286,
"Start date for period": "2022-08-01",
"Value": 500000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 339,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 336,
"Start date for period": "2022-11-01",
"Value": 100000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 356,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 353,
"Start date for period": "2022-08-01",
"Value": 200000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 429,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 426,
"Start date for period": "2022-08-01",
"Value": 200000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 446,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 443,
"Start date for period": "2022-11-01",
"Value": 300000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Stock-based
compensation expense recorded in the Company’s condensed consolidated statements of operations for the three and six months ended
January 31, 2022 resulting from stock options awarded to the Company’s employees, directors and consultants was approximately $0.3
million and $0.8 million, respectively. Of the total expense, $0.2 million and $0.5 million, respectively, was recorded to research and
development and $0.1 million and $0.3 million, respectively was recorded in general and administrative in the Company’s condensed
consolidated statements of operations for the three and six months ended January 31, 2022. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 272,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 269,
"Start date for period": "2021-11-01",
"Value": 300000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 289,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 286,
"Start date for period": "2021-08-01",
"Value": 800000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 339,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 336,
"Start date for period": "2021-11-01",
"Value": 200000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 356,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 353,
"Start date for period": "2021-08-01",
"Value": 500000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 429,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 426,
"Start date for period": "2021-11-01",
"Value": 100000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 446,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 443,
"Start date for period": "2021-11-01",
"Value": 300000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | During
the three and six months ended January 31, 2022, 0 and 568 shares of common stock valued at $0 and approximately $0.04 million, respectively,
were issued to a consultant for services. The common stock share values were based on the closing stock price of the Company’s
common stock on the date the shares were granted. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 52,
"End date for period": "2022-01-31",
"Label": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
"Start character": 51,
"Start date for period": "2021-11-01",
"Value": 0
},
{
"Currency / Unit": "iso4217:USD",
"End character": 101,
"End date for period": "2022-01-31",
"Label": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
"Start character": 100,
"Start date for period": "2021-11-01",
"Value": 0
},
{
"Currency / Unit": "iso4217:USD",
"End character": 125,
"End date for period": "2022-01-31",
"Label": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
"Start character": 121,
"Start date for period": "2021-08-01",
"Value": 40000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | The
fair market value of the six-month call and six-month put are based on the Black-Scholes option valuation model. For the six-month offering
period ended on January 31, 2023, the following assumptions were used: six-month maturity, 2.91% risk free interest, 75.04% volatility,
0% forfeitures and $0 dividends. For the six-month offering period ended on January 31, 2022, the following assumptions were used: six-month
maturity, 0.05% risk free interest, 72.99% volatility, 0% forfeitures and $0 dividends. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 239,
"End date for period": "2023-01-31",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"Start character": 235,
"Start date for period": "2022-08-01",
"Value": 0.0291
},
{
"Currency / Unit": "xbrli:pure",
"End character": 266,
"End date for period": "2023-01-31",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"Start character": 261,
"Start date for period": "2022-08-01",
"Value": 0.7504000000000001
},
{
"Currency / Unit": "xbrli:pure",
"End character": 281,
"End date for period": "2023-01-31",
"Label": "ONCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitures",
"Start character": 280,
"Start date for period": "2022-08-01",
"Value": 0
},
{
"Currency / Unit": "xbrli:pure",
"End character": 301,
"End date for period": "2023-01-31",
"Label": "ONCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitures",
"Start character": 300,
"Start date for period": "2022-08-01",
"Value": 0
},
{
"Currency / Unit": "xbrli:pure",
"End character": 435,
"End date for period": "2022-01-31",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"Start character": 431,
"Start date for period": "2021-08-01",
"Value": 0.0005
},
{
"Currency / Unit": "xbrli:pure",
"End character": 462,
"End date for period": "2022-01-31",
"Label": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"Start character": 457,
"Start date for period": "2021-08-01",
"Value": 0.7299
},
{
"Currency / Unit": "xbrli:pure",
"End character": 477,
"End date for period": "2023-01-31",
"Label": "ONCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitures",
"Start character": 476,
"Start date for period": "2022-08-01",
"Value": 0
},
{
"Currency / Unit": "xbrli:pure",
"End character": 497,
"End date for period": "2023-01-31",
"Label": "ONCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitures",
"Start character": 496,
"Start date for period": "2022-08-01",
"Value": 0
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Approximately
$300 and $1,200 was recorded as stock-based compensation during the six months ended January 31, 2023 and 2022, respectively. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 18,
"End date for period": "2023-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 15,
"Start date for period": "2022-08-01",
"Value": 300
},
{
"Currency / Unit": "iso4217:USD",
"End character": 29,
"End date for period": "2022-01-31",
"Label": "us-gaap:AllocatedShareBasedCompensationExpense",
"Start character": 24,
"Start date for period": "2021-08-01",
"Value": 1200
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Effective
May 15, 2012, the Company adopted a defined contribution savings plan pursuant to Section 401(k) of the Code. The plan is for the benefit
of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum
limits imposed by Internal Revenue Service. The terms of the plan allow for discretionary employer contributions and the Company currently
matches 100% of its employees’ contributions, up to 3% of their annual compensation. The Company’s contributions are recorded
as expense in the accompanying condensed consolidated statements of operations. The Company’s contributions totaled approximately
$9,000 and $54,000 for the three and six months ended January 31, 2023, respectively. The Company’s contributions totaled approximately
$28,000 and $81,000 for the three and six months ended January 31, 2022, respectively. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 237,
"End date for period": "2012-05-15",
"Label": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
"Start character": 234,
"Start date for period": "2012-05-14",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 438,
"End date for period": "2012-05-15",
"Label": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
"Start character": 435,
"Start date for period": "2012-05-14",
"Value": 1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 480,
"End date for period": "2023-01-31",
"Label": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
"Start character": 479,
"Start date for period": "2022-08-01",
"Value": 0.03
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | In
January 2021, the Company entered into a co-promotion agreement with Sirtex, pursuant to which the Company granted Sirtex the option
to co-promote TAVO™-EP for the treatment of anti-PD-1 refractory locally advanced or metastatic melanoma in the U.S., including
its territories and possessions. In consideration for the option, the Company received an upfront, non-refundable payment of $5.0 million
from Sirtex (the “option fee”). The option to co-promote is non-exclusive and may be exercised at any time by Sirtex from
the effective date until 90 days following the receipt by Sirtex of a complete copy of the final BLA filed by the Company with the FDA
(the “option period”). If Sirtex exercises the option, the Company will receive an additional non-refundable and non-creditable
option exercise fee of $25.0 million, comprised of $20.0 million in cash, and $5.0 million for the issuance of common shares of the Company
determined by the average closing price of the stock for the 30 days prior to the date of receipt of the exercise notice for the option. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 393,
"End date for period": "2021-01-31",
"Label": "ONCS:NonrefundablePayment",
"Start character": 390,
"Start date for period": "2021-01-01",
"Value": 5000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 815,
"End date for period": "2021-01-31",
"Label": "ONCS:AdditionalNonrefundableAndNoncreditableOptionExercises",
"Start character": 811,
"Start date for period": "2021-01-01",
"Value": 25000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 843,
"End date for period": "2021-01-31",
"Label": "ONCS:CashToBeReceivedIfOptionExercises",
"Start character": 839,
"Start date for period": "2021-01-31",
"Value": 20000000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 869,
"End date for period": "2021-01-31",
"Label": "ONCS:NonrefundablePayment",
"Start character": 866,
"Start date for period": "2021-01-01",
"Value": 5000000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | The
Company has determined that the co-promotion agreement represents a funded research and development arrangement within the scope of ASC
Subtopic 730-20, Research and Development—Research and Development Arrangements (ASC 730-20). The Company concluded that there
has not been a substantive and genuine transfer of risk related to the co-promotion agreement and the Company’s ongoing development
of TAVO™-EP as there is a presumption that the Company is obligated to repay Sirtex based on the significant related party relationship
that exists between the parties. This significant related party relationship is based on Sirtex’s approximate 8% ownership of the
outstanding shares of the Company’s common stock, and that of its significant equity holder, CGP (which owns 49% of Sirtex), which,
at the time of entering into the agreement, owned approximately 42% of the outstanding shares of the Company’s common stock and
is the Company’s largest shareholder. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 646,
"End date for period": "2021-01-31",
"Label": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
"Start character": 645,
"Start date for period": "2021-01-31",
"Value": 0.08
},
{
"Currency / Unit": "xbrli:pure",
"End character": 863,
"End date for period": "2021-01-31",
"Label": "ONCS:OutstandingSharesPercent",
"Start character": 861,
"Start date for period": "2021-01-31",
"Value": 0.42
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | As
of January 31, 2023, the balance of the Liability under co-promotion agreement – related party relates to the option fee payment
of $5.0 million received from Sirtex. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 139,
"End date for period": "2023-01-31",
"Label": "ONCS:LiabilityUnderCoPromotionAgreementRelatedParties",
"Start character": 136,
"Start date for period": "2023-01-31",
"Value": 5000000
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | On
November 25, 2022 (the “Funding Date”), the Company entered into a Convertible Promissory Note and Security agreement with
GDDL pursuant to which the Company issued a Secured Convertible Promissory Note (the “Note”) to GDDL. The Note has a principal
amount of $2,000,000, bears interest at a rate of 5% per annum until November 25, 2023 and 10% per annum thereafter (the “Interest
Rate”) and matures on November 25, 2024 (the “Maturity Date”), on which date the principal balance and all accrued
interest under the Note shall be due and payable. The Interest Rate will be 10% per annum upon occurrence of an event of default, including,
but not limited to, the failure by the Company to make payment of principal or interest due under the Note on the Maturity Date, and
any commencement by the Company of a case under any applicable bankruptcy or insolvency laws. The principal and interest accrued on the
Note may be prepaid without any further agreement of the parties to the Note, or converted (as described below) upon the agreement of
the parties to the Note, at any time without penalty to the Company. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 304,
"End date for period": "2022-11-25",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 303,
"Start date for period": "2022-11-25",
"Value": 0.05
},
{
"Currency / Unit": "xbrli:pure",
"End character": 346,
"End date for period": "2022-11-25",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 344,
"Start date for period": "2022-11-25",
"Value": 0.1
},
{
"Currency / Unit": "xbrli:pure",
"End character": 577,
"End date for period": "2022-11-25",
"Label": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
"Start character": 575,
"Start date for period": "2022-11-25",
"Value": 0.1
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | Subject
to the consent of GDDL, the Note is convertible into such number of fully paid and non-assessable shares of the Company’s common
stock, par value $0.0001 per share (the “Common Stock”) as determined by dividing (i) any portion of the unpaid principal
and accrued interest of the Note then outstanding by (ii) the greater of (a) the last closing bid price of a share of Common Stock as
reported on the Nasdaq Capital Market (“Nasdaq”) on the date the Company and GDDL agree to such conversion and (b) the average
closing bid price of a share of Common Stock as reported on Nasdaq for the thirty trading days immediately preceding such date, subject
to a share cap of 360,589 shares of Common Stock (the “Share Cap”), representing 19.99% of the total issued and outstanding
shares of Common Stock as of November 25, 2022. | [
{
"Currency / Unit": "xbrli:pure",
"End character": 742,
"End date for period": "2022-11-25",
"Label": "ONCS:CommonStockPercentage",
"Start character": 737,
"Start date for period": "2022-11-25",
"Value": 0.19990000000000002
}
] |
10-Q | 0001493152-23-007478 | 20230313180720 | 20230131 | ONCOSEC MEDICAL Inc | On
December 27, 2022, the Company received a notice from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule
5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2.5 million in stockholders’ equity for continued
listing. The Company has reported a stockholders’ deficit of approximately $5.5 million in this quarterly report on Form 10-Q for
the period ended January 31, 2023, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). The notice has no immediate
impact on the listing of the Company’s common stock, which will continue to be listed and traded on Nasdaq, subject to the Company’s
compliance with the other continued listing requirements. The notice provided the Company with 45 calendar days, or until February 10,
2023, to submit a plan to regain compliance. The Company submitted such a plan to Nasdaq on February 10, 2023, and on February 21, 2023,
the Company received a notice from Nasdaq that it had been granted 180 calendar days from December 27, 2022, or until June 26, 2023,
to regain compliance. There can be no assurance that the Company will be able to regain compliance with all applicable continued listing
requirements. In the event the Company fails to regain compliance within the compliance period, the Company would have the right to a
hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the
hearing process and the expiration of any additional extension period granted by the panel following the hearing. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 222,
"End date for period": "2022-12-27",
"Label": "us-gaap:StockholdersEquity",
"Start character": 219,
"Start date for period": "2022-12-27",
"Value": -2500000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 348,
"End date for period": "2023-01-31",
"Label": "us-gaap:StockholdersEquity",
"Start character": 345,
"Start date for period": "2023-01-31",
"Value": -5500000
}
] |
10-Q | 0001617242-23-000009 | 20230207084543 | 20221231 | Kearny Financial Corp. | On January 26, 2023, the Company declared a quarterly cash dividend of $0.11 per share, payable on February 22, 2023 to stockholders of record as of February 8, 2023. | [
{
"Currency / Unit": null,
"End character": 76,
"End date for period": "2023-01-26",
"Label": "us-gaap:CommonStockDividendsPerShareDeclared",
"Start character": 72,
"Start date for period": "2023-01-26",
"Value": 0.11
}
] |
10-Q | 0001617242-23-000009 | 20230207084543 | 20221231 | Kearny Financial Corp. | Available for sale securities are evaluated to determine if a decline in fair value below the amortized cost basis has resulted from a credit loss or from other factors. An impairment related to credit factors would be recorded through an allowance for credit losses. The allowance is limited to the amount by which the security’s amortized cost basis exceeds the fair value. An impairment that has not been recorded through an allowance for credit losses shall be recorded through other comprehensive income, net of applicable taxes. Investment securities will be written down to fair value through the Consolidated Statement of Income if management intends to sell, or may be required to sell, the securities before they recover in value. The issuers of these securities continue to make timely principal and interest payments and none of these securities were past due or were placed in nonaccrual status at December 31, 2022. Management believes that the unrealized losses on these securities are a function of changes in market interest rates and credit spreads, not changes in credit quality. No allowance for credit losses was recorded at December 31, 2022 on available for sale securities. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 1101,
"End date for period": "2022-12-31",
"Label": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
"Start character": 1099,
"Start date for period": "2022-12-31",
"Value": 0
}
] |
10-Q | 0001617242-23-000009 | 20230207084543 | 20221231 | Kearny Financial Corp. | TDRs are loans where the Company has modified the contractual terms of the loan as a result of the financial condition of the borrower. Subsequent to their modification, TDRs are placed on non-accrual until such time as satisfactory payment performance has been demonstrated, at which time the loan may be returned to accrual status. On a case-by-case basis, the Company may agree to modify the contractual terms of a loan to assist a borrower who may be experiencing financial difficulty, as well as to preserve the Company’s position in the loan. If the borrower is experiencing financial difficulties and a concession has been made at the time of such modification, the loan is classified as a TDR. The Company had TDRs totaling $18.4 million and $22.2 million as of December 31, 2022 and June 30, 2022, respectively. The allowance for credit losses associated with the TDRs presented in the tables below totaled $331,000 and $365,000 as of December 31, 2022 and June 30, 2022, respectively. As of December 31, 2022, the Company had commitments to lend additional funds totaling $69,000 to borrowers whose loans had been restructured in a TDR. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 737,
"End date for period": "2022-12-31",
"Label": "us-gaap:FinancingReceivableModificationsRecordedInvestment",
"Start character": 733,
"Start date for period": "2022-12-31",
"Value": 18400000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 755,
"End date for period": "2022-06-30",
"Label": "us-gaap:FinancingReceivableModificationsRecordedInvestment",
"Start character": 751,
"Start date for period": "2022-06-30",
"Value": 22200000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 924,
"End date for period": "2022-12-31",
"Label": "krny:FinancingReceivableTroubledDebtRestructuringAllowanceForCreditLoss",
"Start character": 917,
"Start date for period": "2022-12-31",
"Value": 331000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 937,
"End date for period": "2022-06-30",
"Label": "krny:FinancingReceivableTroubledDebtRestructuringAllowanceForCreditLoss",
"Start character": 930,
"Start date for period": "2022-06-30",
"Value": 365000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 1089,
"End date for period": "2022-12-31",
"Label": "us-gaap:LoansAndLeasesReceivableImpairedCommitmentToLend",
"Start character": 1083,
"Start date for period": "2022-12-31",
"Value": 69000
}
] |
10-Q | 0001617242-23-000009 | 20230207084543 | 20221231 | Kearny Financial Corp. | During the three months and six months ended December 31, 2022, there were charge-offs of $5,000 and $15,000, respectively, related to TDRs. During the three months and six months ended December 31, 2021, there were no charge-offs related to TDRs. During the three months and six months ended December 31, 2022, there were two TDR defaults totaling $170,000. During the three months and six months ended December 31, 2021, there were no defaults of TDRs. | [
{
"Currency / Unit": "iso4217:USD",
"End character": 96,
"End date for period": "2022-12-31",
"Label": "us-gaap:FinancingReceivablesImpairedTroubledDebtRestructuringWriteDown",
"Start character": 91,
"Start date for period": "2022-10-01",
"Value": 5000
},
{
"Currency / Unit": "iso4217:USD",
"End character": 108,
"End date for period": "2022-12-31",
"Label": "us-gaap:FinancingReceivablesImpairedTroubledDebtRestructuringWriteDown",
"Start character": 102,
"Start date for period": "2022-07-01",
"Value": 15000
}
] |
Subsets and Splits